IGF-1 LR3 peptide is a manufactured, synthetic, modified version of insulin-like growth factor-1. Because IGF-1 LR3 does not seem to bind to IGF-1 binding proteins well, it appears to remain active up to 120 times longer than normal IGF-1. Studies suggest this may result in an enhanced half-life for the peptide and, thus, improved activity. Research indicates that IGF-1 LR3 may enhance cell division and growth, increase metabolism, and support muscle tissue recovery, and hypertrophy by hindering myostatin.
IGF1-LR3 Peptide: What is it?
IGF1-LR3 is an altered version of insulin-like growth factor-1. The full name of the compound is insulin-like growth factor-1 long arginine 3. Investigations purport that all IGF-1 derivatives may play considerable roles in cell division, cell proliferation, and cell-to-cell communication. Though it is hypothesized to have similar effects, IGF-1 LR3 does not seem to adhere to IGF-binding proteins as strongly as IGF-1. Findings imply that this may result in IGF1-LR3 staying in the bloodstream 120 times longer than IGF-1. IGF1-LR3 has a prolonged half-life as a result of structural alterations. The peptide is created by linking 13 amino acids to the N-terminal of IGF-1 and moving the glutamic acid to an arginine residue at placement 3 of IGF-1.
IGF-1 LR3 Peptide and Glucocorticoid Signaling
Glucocorticoids, released primarily by the adrenal glands, are compounds that may mitigate pain and decrease inflammation in autoimmune illnesses, neurological injury, cancer, and more. Unfortunately, glucocorticoids have several undesirable effects, such as muscle cell wasting, decrease in metabolic rate, and weakening of bone density. There is some attraction in evaluating IGF1-LR3 to potentially reduce the action of glucocorticoids and thus allow for a more effective approach. Receptor Grade IGF-1 LR3 is limited to educational and scientific studies, not for human and animal consumption. Only buy IGF1-LR3 if you are an academic or a professional.
IGF-1 LR3 Peptide and Cell Longevity
Scientists speculate that IGF1-LR3 may promote tissue restoration and upkeep throughout the organism, making it a potentially protective molecule against cell deterioration and the onset of cell aging. Research in farm animals indicates that IGF1-LR3 presentation may exert practical impacts for offsetting the impacts of cellular aging. Ongoing studies in mice seek to determine if IGF1-LR3 might be useful in preventing the evolution of various conditions, such as dementia, muscle atrophy, and kidney illness. This research purports that IGF-1 presentation may prolong cell life.
IGF-1 LR3 Peptide and Myostatin
Myostatin (growth differentiation factor 8) is a muscle protein believed to primarily inhibit the evolution and differentiation of muscle cells. While this role is important to prevent unregulated hypertrophy and ensure adequate healing following damage, there are times when hindering myostatin could be of benefit.
Preventing myostatin from action may be useful in illnesses like Duchenne muscle dystrophy (DMD) or in other cases of muscle loss. In these circumstances, impeding this natural enzyme might slow muscle degradation, keep strength, and stave off morbidity. In mouse research models of DMD, it has been speculated that IGF1-LR3 and other IGF-1 derivatives may be capable of counteracting aspects of myostatin action to shield muscle cells and prevent apoptosis. IGF1-LR3, thanks to its long half-life, is believed to be practical in neutralizing myostatin and appears to act by activating a muscle protein called MyoD. MyoD is the protein normally activated by physical activity or tissue damage and is responsible for muscle hypertrophy.
IGF-1 LR3 Peptide and Fat Metabolism and Diabetes
It has been theorized that IGF1-LR3 may indirectly boost fat metabolism by binding to both the IGF-1R receptor and the insulin receptor. These actions enhance glucose uptake from the blood by muscle, nerve, and liver cells. This may decrease blood sugar levels, triggering adipose tissue and the liver to begin breaking down glycogen and triglycerides. This produces a net decline in fatty tissue and net energy expenditure (i.e., net catabolism).
Given its possible role in reducing blood sugar levels, it should be no surprise that IGF1-LR3 has been speculated to reduce insulin levels and the need for exogenous insulin in diabetes. This usually translates into a 10% decrease in insulin needed to maintain the same blood sugar levels. This fact may aid scientists in understanding how to decrease insulin concentrations in research models that have lower insulin sensitivity and may even give insight into preventing type 2 diabetes in the first place.
Note: Please note that none of the substances mentioned in this article have been approved for human or animal consumption and should, therefore, not be acquired or utilized by unlicensed individuals outside of research facilities such as laboratories. Article in educational reading purpose only.
References
[i] “Adipose Tissue-Derived Stem Cell Secreted IGF-1 Protects Myoblasts from the Negative Effect of Myostatin.” [Online]. Available: https://www.hindawi.com/journals/bmri/2014/129048/.
[ii] N. Li, Q. Yang, R. G. Walker, T. B. Thompson, M. Du, and B. D. Rodgers, “Myostatin Attenuation In Vivo Reduces Adiposity, but Activates Adipogenesis,” Endocrinology, vol. 157, no. 1, pp. 282–291, Jan. 2016.
[iii] E. Corpas, S. M. Harman, and M. R. Blackman, “Human growth hormone and human aging,” Endocr. Rev., vol. 14, no. 1, pp. 20–39, Feb. 1993
[iv] W. E. Sonntag, A. Csiszar, R. deCabo, L. Ferrucci, and Z. Ungvari, “Diverse roles of growth hormone and insulin-like growth factor-1 in mammalian aging: progress and controversies,” J. Gerontol. A. Biol. Sci. Med. Sci., vol. 67, no. 6, pp. 587–598, Jun. 2012.
[v] “IGF-I/IGFBP system: metabolism outline and physical exercise. – PubMed – NCBI.” [Online]. Available: https://www.ncbi.nlm.nih.gov/pubmed/22714057.
[vi] B. Y. Hanaoka, C. A. Peterson, C. Horbinski, and L. J. Crofford, “Implications of glucocorticoid therapy in idiopathic inflammatory myopathies,” Nat. Rev. Rheumatol., vol. 8, no. 8, pp. 448– 457, Aug. 2012
[vii] A Philippou, A Halapas, M Maridaki, M Koutsilieris – J Musculoskelet Neuronal Interact, 2007 [Semantic Scholar]
